Navigation Links
BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
Date:10/31/2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the signing of an amendment to the lease with Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) at its 301 Binney Street facility in Cambridge, Massachusetts.  As a result of this lease extension and phased expansion totaling approximately 93,000 square feet, Ironwood's occupancy in the five-story, state-of-the-art facility will increase to approximately 303,000 square feet. The term of the lease now extends through January 31, 2018.

Commenting on the lease amendment with Ironwood, Alan D. Gold, Chairman and Chief Executive Officer of BioMed Realty, said, "We are delighted to expand and extend our partnership with Ironwood Pharmaceuticals and continue supporting their ongoing efforts to discover, develop and commercialize medicines. With this second significant expansion of its footprint at 301 Binney within the past three years, Ironwood continues to manage its growth in a prudent, measured fashion in the heart of Cambridge, the leading global life science center."

With this latest lease expansion and extension for Ironwood, BioMed Realty has leased approximately 600,000 square feet of laboratory and office space in the Cambridge-Boston market within the past 24 months.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 13.1 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have well-established reputations as centers for scientific research.  Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions, developments and other investments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in foreign, domestic and local economies, changes in interest rates and foreign currency exchange rates, and volatility in the securities markets; ownership of properties outside of the United States that subject the company to different and potentially greater risks than those associated with the company's domestic operations; risks associated with the company's investments in loans, including borrower defaults and potential principal losses; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
2. Carnegie Mellon University Biomedical Engineers Lead Collaborative Team Developing New Astro Surgery Tools for NASA Deep Space Missions
3. BioMed Realty Trust Converts $156.4 Million Of Its Senior Unsecured Term Loan To 100 Million Pounds Sterling
4. BioMed Diagnostics Microbiology Diagnostic Devices Now Available Worldwide Through Distribution Agreement With VWR International, LLC
5. The Biomedical Device Industry in America: Challenges at Home and Abroad
6. 81,200 Square Foot Lease Extension In San Diego Through 2018 Signed By Vertex Pharmaceuticals And BioMed Realty
7. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
8. Fluke Biomedical device first to achieve environmentally-friendly label
9. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
10. Fluke Biomedical launches speedy new ProSim™ SPOT Light SpO2 Functional Tester
11. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... ... of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused ... half the issue representing international (non-US) based authors, the third volume of PXJ ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life ... better understand life insurance throughout various life stages. , The site launched on ... needs calculator and content specific to the times when life insurance matters most. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... for the 2016 Main Residency Match® (“the Match”), the system through which U.S. ... teaching institutions. A record-high 30,750 positions were placed in the 2016 Match, and ...
(Date:5/2/2016)... New York, NY (PRWEB) , ... May 02, 2016 , ... ... Highlighting the year’s best in pet gear and toys, leading product review site ... TTPM Pets Paw of Excellence Awards at their Spring Showcase at the Metropolitan ...
Breaking Medicine News(10 mins):